



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

AUG - 3 1999

#22

Margaret Brumm
Eli Lilly and Company
Patent Division/MMB
Lilly Corporate Center
Indianapolis, IN 46285

Re: Patent Term Extension
Application for
U.S. Patent No. 4,808,614

Dear Ms. Brumm:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 4,808,614 for a period of 1,537 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products).

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

Karin Tyson
Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

cc: David T. Read
Acting Director Regulatory Policy Staff, CDER
Food and Drug Administration
1451 Rockville Pike, HFD-7
Rockville, MD 20852

Re: GEMZAR® (gimcitabine)
FDA Docket No. 96E-0314